19-Sep-2025 2:11 PM CST - Seeking Alpha Caris Life Sciences: Impressive Growth, But Lock-Up Expiry Looms Caris Life Sciences stands out for its broad molecular and AI-driven cancer diagnostics but faces upcoming volatility as the IPO lock-up expires on 15 December 2025. CAI's revenue growth is robust, driven primarily by molecular profiling, but overdependence on this segment and execution across diverse fronts pose risks.
1-Aug-2025 10:14 PM CST - Seeking Alpha C3.ai: Take Advantage Of CEO Volatility To Buy Upgrade your portfolio! C3.ai is a strong buy with explosive growth, top-tier partnerships, and AI exposure at a discount. See more on AI stock here.
18-May-2025 7:31 AM CST - Seeking Alpha JEPI: Highest Dividend Since December 2022, Battle-Tested Discover why JEPI is a strong buy for income investors. Yielding 8%, it offers resilience, low volatility, and diversified large-cap exposure.
19-Sep-2025 2:11 PM CST - Seeking Alpha Caris Life Sciences: Impressive Growth, But Lock-Up Expiry Looms Caris Life Sciences stands out for its broad molecular and AI-driven cancer diagnostics but faces upcoming volatility as the IPO lock-up expires on 15 December 2025. CAI's revenue growth is robust, driven primarily by molecular profiling, but overdependence on this segment and execution across diverse fronts pose risks.
1-Aug-2025 10:14 PM CST - Seeking Alpha C3.ai: Take Advantage Of CEO Volatility To Buy Upgrade your portfolio! C3.ai is a strong buy with explosive growth, top-tier partnerships, and AI exposure at a discount. See more on AI stock here.
18-May-2025 7:31 AM CST - Seeking Alpha JEPI: Highest Dividend Since December 2022, Battle-Tested Discover why JEPI is a strong buy for income investors. Yielding 8%, it offers resilience, low volatility, and diversified large-cap exposure.
